John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

The GETAID IBD National survey Volume 26, issue 2, Février 2019

  • [1] Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012 ; 142 : 46-54.
  • [2] Hoivik M.L., Moum B., Solberg I.C. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013;62:368-375.
  • [3] Jess T., Frisch M., Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11:43-48.
  • [4] Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut 2017 ; 66 : 588-596.
  • [5] van der Valk M.E., Mangen M.J., Severs M. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up. PLoS One. 2016;11:e0142481.
  • [6] Burisch J., Vardi H., Pedersen N. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. Inflamm Bowel Dis. 2015;21:121-131.
  • [7] Panes J., O’Connor M., Peyrin-Biroulet L. Improving quality of care in inflammatory bowel disease: what changes can be made today? J Crohns Colitis. 2014;8:919-926.